Seamless Therapeutics GmbH receives $12.5 million (€11.8 million) seed funding. The aim is to accelerate the further development of a novel genome editing platform based on designer recombinases. The company's recombinase platform is capable of programming a widely used and established molecular biology tool to enable targeted intervention at any location in the genome.

You can find more information here.

Seamless Therapeutics GmbH is supported by the Federal Ministry of Education and Research (BMBF) as part of the "Founding Initiative Biotechnology" (GO-Bio).

The company was founded by Prof Dr Frank Buchholz (Dean of Research at the Faculty of Medicine and Head of Medical Systems Biology at the University Cancer Centre of the Technical University of Dresden) and the Seamless Therapeutics GmbH employees Dr Anne-Kristin Heninger (Chief Executive Officer), Dr Felix Lansing (Chief Scientific Officer), Dr Maciej Paszkowski-Rogacz and Dr Teresa Rojo Romanes.